SIR 2017

1 stories · following the connections

Business

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer

By Nasdaq OMXMar 8, 2017, 11:00 AM UTC